Kjell Mortier | Fund Manager | Novalis Biotech Acceleration Fund
Prior to working for Novalis Biotech Incubation, Dr. Kjell Mortier acquired approximately 20 years of experience in the biotech industry working in various scientific roles. At Ablynx, now part of Sanofi, he was responsible for the bioanalytical and immunogenicity part of dedicated clinical programs. At Eurofins, a leading CRO in the pharma, food and environmental industry, he supported the CMC-analytical part for various customers in the pharma industry. Kjell also obtained certification for financial analysis at EHSAL Management School.
(Ghent, Belgium) is an early-stage venture capital investor in technologies that revolutionize healthcare. The fund’s core competence lies in digitalization in the life sciences with a focus on “enabling technologies” within research and manufacturing technologies, genomics, bioinformatics, diagnostics, and personalized medicine.
Powered by: Hyphen Projects | Connect | Join Global Investor Forum | |||
Privacy Policy Terms & Conditions Chamber of Commerce: 32110979 VAT no: NL8184.34.491.B01 |
| Register here
|
© Copyright 2023 by Hyphen Projects